# Research articles and analytical reports

> The Peptide Program reading list — The Peptide Program reading list covers urine screening, unknown preparations, fat-metabolism assays and human oral AOD-9604 tolerability.

**Reading list**

The urine-screening method opens the collection: a named peptide panel with reported detection limits. The other reports add context for AOD-9604.

## Screening and identification

The [direct urine-injection screening method](https://pubmed.ncbi.nlm.nih.gov/26578461/) includes AOD-9604 among the small peptides covered by its analytical procedure. The [sports drug-testing review](https://pubmed.ncbi.nlm.nih.gov/26213263/) places it within the wider mass-spectrometric work. The [Belgian seized-preparation case report](https://pubmed.ncbi.nlm.nih.gov/24976118/) concerns identification in unknown material.

My favourite pairing is the screen with named targets and the case report that begins with unknown material.

## Biological response

The [rat fat-pad study of hGH 177–191](https://pubmed.ncbi.nlm.nih.gov/8358331/) distinguishes antilipogenic from lipolytic activity. The [AOD-9604 metabolic study](https://pubmed.ncbi.nlm.nih.gov/11146367/) examines the synthetic C-terminal domain. The [beta-3 receptor knockout experiment](https://pubmed.ncbi.nlm.nih.gov/11713213/) separates chronic and acute responses in mice. These are different preparations and experimental questions.

## Oral exposure

The [oral safety and tolerability report](https://www.jofem.org/index.php/jofem/article/view/157/194) concerns adults with obesity. The [sports-medicine review](https://pubmed.ncbi.nlm.nih.gov/41966639/) includes AOD-9604 among unapproved compounds and discusses the limits of rigorous human safety evidence across musculoskeletal and performance applications.

I take the narrower trial report and the broader review as invitations to ask about the particular population, purpose and route involved.

## References

[1] Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry https://pubmed.ncbi.nlm.nih.gov/26578461/
[2] Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604 https://pubmed.ncbi.nlm.nih.gov/24976118/
[3] Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone https://pubmed.ncbi.nlm.nih.gov/11146367/
[4] Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone https://pubmed.ncbi.nlm.nih.gov/8358331/
[5] The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice https://pubmed.ncbi.nlm.nih.gov/11713213/
[6] Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans https://www.jofem.org/index.php/jofem/article/view/157/194
[7] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance https://pubmed.ncbi.nlm.nih.gov/41966639/
[8] Human sports drug testing by mass spectrometry https://pubmed.ncbi.nlm.nih.gov/26213263/

---

Here I pursue the published AOD-9604 research from chemical identification to human tolerability; The Peptide Program is an editorial site, with no treatment service or medical advice.